Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | CRHBP | P24387 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 4/20 | 0.48 |
| ▸ | TP53 | P04637 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.46 |
| ▸ | MEN1 | O00255 | 4/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | DRD4 | P21917 | 1/20 | 0.40 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22874585 | 0.69 | MAPT (0.65) | MAPTSMN1; SMN2MEN1KMT2AALDH1A1 | |
| SCHEMBL27541379 | 0.68 | DBH (0.51) | KDM4ECYP3A4CYP2C9CRHBPCYP2C19 | |
| SCHEMBL2175595 | 0.68 | MAPK14 (0.43) | SMN1; SMN2ALDH1A1L3MBTL1LMNA | |
| SCHEMBL2174190 | 0.67 | POLB (0.57) | KDM4ESMN1; SMN2MEN1KMT2AALDH1A1 | |
| SCHEMBL2177234 | 0.66 | MAPK14 (0.44) | SMN1; SMN2LMNA | |
| SCHEMBL2178094 | 0.66 | EPHX2 (0.47) | SMN1; SMN2LMNA | |
| SCHEMBL2175946 | 0.65 | LMNA (0.46) | SMN1; SMN2MEN1KMT2ALMNA | |
| SCHEMBL2174653 | 0.64 | LMNA (0.51) | KDM4EMAPTTP53SMN1; SMN2MEN1 | |
| SCHEMBL2178830 | 0.64 | MAPK14 (0.42) | SMN1; SMN2LMNA | |
| SCHEMBL2177202 | 0.64 | MAPK14 (0.53) | PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1948601-A1 | FAB I INHIBITOR AND PROCESS FOR PREPARING SAME | Crystalgenomics, Inc. (KR) | 2008-07-30 | — | — | EP | claimed |
| US-20070135465-A1 | Fab I Inhibitor and Process for Preparing Same | CRYSTALGENOMICS, INC. (KR) | 2007-06-14 | — | — | US | claimed |
| WO-2007043835-A1 | FAB I INHIBITOR AND PROCESS FOR PREPARING SAME | CRYSTALGENOMICS, INC. (KR) | 2007-04-19 | — | — | WO | claimed |
| US-7973060-B2 | Fab I inhibitor and process for preparing same | CRYSTALGENOMICS, INC. (KR) | 2011-07-05 | — | — | US | disclosed |
| EP-1948601-A1 | FAB I INHIBITOR AND PROCESS FOR PREPARING SAME | Crystalgenomics, Inc. (KR) | 2008-07-30 | — | — | EP | disclosed |
| US-20070135465-A1 | Fab I Inhibitor and Process for Preparing Same | CRYSTALGENOMICS, INC. (KR) | 2007-06-14 | — | — | US | disclosed |
| WO-2007043835-A1 | FAB I INHIBITOR AND PROCESS FOR PREPARING SAME | CRYSTALGENOMICS, INC. (KR) | 2007-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135465-A1 | Fab I Inhibitor and Process for Preparing Same | TFPI, TFPI2, FCGRT | KDM4E 3785/4885CYP3A4 2161/4885CYP2C9 2630/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.